The United States has initiated the first human trial of a gene therapy designed to combat the effects of aging. The experimental treatment, administered in early June, focuses on rejuvenating cells within the human eye. Scientists believe this marks a significant step towards potentially reversing age-related decline, though the therapy is currently limited in scope. The trial represents a novel approach to tackling aging at a genetic level, moving beyond traditional methods. While the long-term effects remain unknown, researchers are optimistic about the potential for broader applications in the future. This pioneering treatment offers a glimpse into a future where age-related diseases could be prevented or even reversed.